| 33.59 2.04 (6.47%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.96 | 1-year : | 47.61 |
| Resists | First : | 35.92 | Second : | 40.77 |
| Pivot price | 32.97 |
|||
| Supports | First : | 28.09 | Second : | 23.37 |
| MAs | MA(5) : | 32.29 |
MA(20) : | 32.43  |
| MA(100) : | 33.09 |
MA(250) : | 22.11 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 40.3 |
D(3) : | 39.7 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 53 | Low : | 12.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NGNE ] has closed below upper band by 41.6%. Bollinger Bands are 38.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.03 - 34.16 | 34.16 - 34.31 |
| Low: | 31.81 - 31.95 | 31.95 - 32.11 |
| Close: | 33.33 - 33.55 | 33.55 - 33.81 |
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Fri, 10 May 2024
Neurogene Inc. Optimistic on NGN-401 Trial Progress - TipRanks.com - TipRanks
Fri, 10 May 2024
Neurogene Inc. Forecasted to Post Q1 2025 Earnings of ($0.84) Per Share (NASDAQ:NGNE) - Defense World
Fri, 03 May 2024
Neurogene Inc. (NASDAQ:NGNE) Expected to Post Q1 2024 Earnings of ($1.19) Per Share - Defense World
Wed, 01 May 2024
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Mon, 22 Apr 2024
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett ... - Business Wire
Tue, 26 Mar 2024
Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers (NASDAQ:NGNE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 78 (%) |
| Shares Short | 1,020 (K) |
| Shares Short P.Month | 906 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | 0 |
| PEG Ratio | -0.4 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|